Published: May 18, 2021
IsoPlexis adds Switzerland as the latest country with access to their unique functional single-cell proteomics platform, adding to their existing partnerships across Asia and Europe.
BRANFORD, Conn., May 18, 2021 /PRNewswire/ --
IsoPlexis, the leader in single-cell proteomics, today announced an exclusive agreement with
Bucher Biotec AG, a Swiss distributor company representing some of the most advanced US, European, and Asian manufacturers of highly innovative life science research instrumentation, associated reagents, and consumables. This agreement follows IsoPlexis' recent global distributor announcements, throughout Asia and Europe.
IsoPlexis' IsoLight platform has received numerous awards, recognized as both The Scientist's and Fierce Life Science's #1 innovation for the ability to provide single-cell sensitivity with highly multiplexed and quantitative functional ELISA detection together for the first time. IsoPlexis' IsoLight was awarded the global Red Dot Design Award for its ease of use, and the 18-inch IsoSpark system has received two Red Dot Design Awards for High Design Quality & Innovative Product. These systems are now available to customers in Singapore, Malaysia, China, Taiwan, Japan, South Korea, Spain, Portugal, and Switzerland through IsoPlexis' latest agreements.